The influence of edema on the bisoprolol blood concentration after bisoprolol dermal patch application: A case-control study

Medicine (Baltimore). 2021 Sep 24;100(38):e27354. doi: 10.1097/MD.0000000000027354.

Abstract

Background: Beta-blocking is important for critically ill patients. Although some patients are required to continue taking beta-blockers after they no longer need critical care, some of these patients have impaired swallowing abilities. Bisoprolol dermal patches have recently been introduced and appear to be a good alternative to oral bisoprolol tablets. However, it is still unclear whether the pharmacodynamics of such patches are affected by edema in patients who have experienced critical care. This study aimed to clarify the effects of systemic edema on beta-blocker absorption from dermal patches in critically ill patients.

Method: Patients who exhibited tachycardia and impaired swallowing function after critical care were included in this study. They were assigned to either the edema group (n = 6) or no edema group (n = 6) depending on the presence/absence of edema in the lower extremities. A bisoprolol dermal patch was pasted onto each subject, and the blood bisoprolol concentration was checked at 8 timepoints over the next 24 hours. The area under the serum concentration time curve, maximum concentration observed (Cmax), and time of maximum concentration observed were also examined.

Result: The mean blood bisoprolol concentrations of the 2 groups were not significantly different at 2, 4, 6, 8, 10, 12, 16, or 24 hours after the patch application. The area under the serum concentration time curve and maximum concentration observed were not different between the groups. The mean heart rates of the 2 groups were not significantly different at 6, 12, or 24 hours after the patch application (Student t test, P = .0588, P = .1080, and P = .2322, respectively).

Conclusion: In this study, the blood concentration of bisoprolol and its heart rate-reducing effects after bisoprolol dermal patch application might not be affected by systemic edema in the lower extremities.

MeSH terms

  • Administration, Cutaneous
  • Adrenergic beta-1 Receptor Antagonists / administration & dosage
  • Adrenergic beta-1 Receptor Antagonists / blood
  • Adrenergic beta-1 Receptor Antagonists / pharmacokinetics*
  • Aged
  • Aged, 80 and over
  • Bisoprolol / administration & dosage
  • Bisoprolol / blood
  • Bisoprolol / pharmacokinetics*
  • Case-Control Studies
  • Edema / metabolism*
  • Female
  • Humans
  • Male
  • Skin Absorption*

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Bisoprolol